ReviewDrug design, development and therapy2026
Advancing Drug Delivery with Biodegradable Molecularly Imprinted Polymers: From Design to Clinical Prospects.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecularly imprinted polymers (MIPs) have emerged as promising materials for drug delivery systems, offering various advantages in terms of selectivity, stability, modified/smart release properties, and targeted therapy. Despite decades of development, the clinical translation of MIP-DDS remains limited, mainly due to concerns regarding long-term safety, biodegradability, and regulatory acceptance. To overcome these limitations, current research focuses on designing MIP-DDS by incorporating degradable monomers, crosslinkers, and polymer architectures. The selection of monomers and crosslinkers, as well as polymerization strategies, critically influences not only the efficiency of the recognition sites formed but also the rate of degradation and drug release, which can occur through stimuli-responsive bond cleavage, hydrolysis, or surface erosion. Beyond synthetic considerations, systemic evaluation of the biocompatibility, toxicity, and degradation mechanisms of MIP-DDS is essential to support regulatory approval and clinical implementation. Therefore, this article discusses current advances, key design strategies, degradation mechanisms, and translational challenges of biodegradable MIP-DDS, highlighting the development of clinically viable imprinted drug delivery platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.